skip to main content

Benign prostatic enlargement with persistent nocturia due to idiopathic nocturnal polyuria — MSRA MCQ

Instant feedback + full explanation. One question, done properly.

ModerateBPHBenign prostatic enlargement with persistent nocturia due to idiopathic nocturnal polyuriaMSRA

A 69-year-old man with benign prostatic enlargement has taken tamsulosin MR 400 micrograms daily for 5 months. His hesitancy, weak stream and incomplete emptying have improved substantially. He remains troubled by waking three to four times nightly to pass large volumes of urine. Urine culture is negative, eGFR is 68 mL/min/1.73 m², and post-void residual volume is 55 mL. A 3-day frequency-volume chart confirms nocturnal polyuria. Diabetes mellitus, heart failure, dependent oedema, obstructive sleep apnoea and diuretic use have been excluded. He has already reduced evening fluid intake and caffeine without benefit. His blood pressure is 132/78 mmHg and serum sodium is 140 mmol/L. He takes no medicines associated with hyponatraemia. What is the most appropriate next management plan?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: EStart desmopressin oral lyophilisate 50 micrograms at bedtime, advise overnight fluid restriction, and check serum sodium in the first week and at 1 month

Explanation lettering: C = shown as A · E = shown as B · B = shown as C · A = shown as D · D = shown as E

This is persistent nocturia caused by confirmed nocturnal polyuria rather than residual bladder outlet obstruction: his voiding symptoms and residual volume have improved on tamsulosin, while the frequency-volume chart shows excessive nocturnal urine production. Relevant secondary causes have been excluded and conservative measures have failed. NICE supports oral desmopressin in this setting. For a man, the licensed Noqdirna dose is 50 micrograms sublingually 1 hour before bedtime. Fluid intake should be minimised from 1 hour before until 8 hours after dosing. In people aged 65 years or over, sodium must be normal before treatment and rechecked in the first week and at 1 month because of hyponatraemia risk. A is inappropriate because increasing alpha-blockade does not address nocturnal polyuria and may increase adverse effects. B would be reasonable for persistent urgency/frequency due to overactive bladder, but the chart identifies excess nocturnal urine production. C is a NICE-considered alternative for nocturnal polyuria, but desmopressin is appropriate here after conservative measures where contraindications are absent. E is not indicated for uncomplicated LUTS without haematuria, recurrent infection, suspected malignancy or other evidence of urinary tract abnormality.

Reference: NICE CG97: Lower urinary tract symptoms in men: management — Recommendations (Last updated June 2015; last reviewed December 2024) — https://www.nice.org.uk/guidance/cg97/chapter/recommendations Noqdirna 50 micrograms oral lyophilisate — Summary of Product Characteristics (2026) — https://www.medicines.org.uk/emc/product/4372/smpc